January 14, 2009—Seoul, Korea: HanAll Pharmaceutical Co., Ltd., a leading R&D pharmaceutical company in Korea, is pleased to announce the appointment of Andrew J. Gorman, Ph.D. as Vice President & Chief, Corporate Development. Dr. Gorman will be responsible for leading business development, product development and operations outside Korea. He will be based in the U.S. at the HanAll Pharmaceutical International, Inc. (HPI, Inc.) office located in Rockville, MD.
Dr. Gorman brings over 15 years of pharmaceutical industry R&D and business development experience. He has held positions of increasing responsibility at Hoechst Marion Roussel (now Sanofi Aventis), Bristol Myers Squibb, CJ Pharma, Transave Inc., and Paramount BioSciences. He has been involved in various transactions on a global basis in the biotechnology, clinical development and commercial areas. He received his B.S. in Biology/Mathematics from Baylor University and his Ph.D. in Physiology/Pharmacology from the University of Texas Health Science Center at San Antonio.
Dr. SungWuk Kim, CEO & President of Hanall stated: “We are extremely pleased and feel very fortunate to have an experienced pharma executive in Dr. Gorman bringing many years of large pharma and biotech experience, an extensive global network and a global business perspective that will be critical in achieving our goal of a strong a global presence. As we initiate our first clinical trials with our XC Hybrid Combination Cardiology products this year, Dr. Gorman’s scientific, business and operational leadership will be a significant asset to our company. In addition, identifying and securing partnerships with major global and regional pharma companies is a key business strategy for our company. Dr. Gorman certainly brings the vast experience and global network for HanAll to establish formidable, strategic partnerships.”
About HanAll Pharmaceuticals
HanAll is a top 10 Korean-based R&D pharma company established in 1973. The company has developed over 30 different combinations of cardiology products through its innovative and proprietary XC Hybrid Combination formulation technology. XC Hybrid Combination formulation provides the efficacy, safety and lack of drug-drug interaction of monotherapy and also provides the benefits of cardiology combination drugs desired by patients and prescribers. This is achieved by a unique time separation and delayed release PK profile of the combination products. HanAll will begin Phase Ib/II clinical studies in the U.S. and Korea in April 2009 with its lead product, HL 007, a double matrix combination formulation of simvastatin (immediate release) and amlodipine (delayed release). Bioequivalency and drug interaction studies will be carried out. A second U.S. clinical trial is scheduled for later this year to confirm the time-delayed release product profile of HanAll’s second lead product, HL 008, a combination of losartan and amlodipine. HanAll also conducts R&D in the areas of biologics, metabolism/diabetes, antivirals and dermatology biotherapeutics. The company seeks global or regional partners to commercialize their innovative programs.
